News and views
June 2014 Br J Cardiol 2014;21:62–3
Can we trust our ECG machines?
The article on pages 47–8, by Drs Derek Rowlands and Philip Moore, highlights the importance of maintaining our clinical skills at electrocardiogram (ECG) interpretation. The authors touch upon the unsatisfactory reliance on computer analyses. The frequent inaccuracy of computer-generated ECG interpretation is well recognised, yet how many of us in primary care, still fall back on this? The machine diagnostics can so easily mislead us. Always check it yourself, and consider your findings in conjunction with the clinical presentation. Today, we’re doing a confidence test …...
June 2014 Br J Cardiol 2014;21:60–1
Managing outpatients: a personal approach
We continue our series in which Consultant Interventionist Dr Michael Norell takes a sideways look at life in the cath lab…and beyond. In this column, he considers how we manage the often dreaded outpatients’ clinics....
June 2014 Br J Cardiol 2014;21:51
Correspondence: aggressive risk factor modification: 30 year follow-up of IHD and non-haemorrhagic stroke
Correspondence from the world of cardiology...
June 2014 Br J Cardiol 2014;21:51
Correspondence: assessing the clinical benefits of drugs for dyslipidaemia
Correspondence from the world of cardiology...
June 2014 Br J Cardiol 2014;21:51
Correspondence: is it time for a re-assessment of EECP in the UK?
Correspondence from the world of cardiology...
April 2014 Br J Cardiol 2014;21:56–7 Online First
News from ACC.14
The 63rd Annual Scientific Session of the American College of Cardiology (ACC) − held in Washington DC, USA from March 29th−31st 2014 − held several surprises, including a UK study showing heparin to be better than the much more expensive bivalirudin as an antithrombotic in primary PCI, and great disappointment from the first controlled trial of renal denervation for hypertension. ...
April 2014 Br J Cardiol 2014;21:52–3 Online First
JBS3 recommends lifetime CVD risk estimation
A new emphasis on estimating the lifetime risk of future cardiovascular disease (CVD) – rather than the current 10-year risk – has been recommended by the Joint British Societies in their report Consensus Recommendations for the Prevention of Cardiovascular Disease (JBS3). The new recommendations will encompass much more of the population, such as young individuals and women, who may have a high lifetime risk of CVD but a low 10-year risk using current guidance. ...
April 2014 Br J Cardiol 2014;21:(2) Online First
A walk around the right heart
Dr Lindsey Tilling reports from the recent British Society of Heart Failure day for training and revalidation, held in Glasgow...
March 2014 Br J Cardiol 2014;21:9
NICE guidance updates on statins and secondary prevention
Draft guidance on statins The National Institute for Health and Care Excellence (NICE) is recommending that the threshold for starting statins for the preventive treatment of cardiovascular disease (CVD) is halved from a 20% risk of developing CVD over 10 years to a 10% risk. This draft guidance – an update on its 2008 lipid modification guidance – follows new evidence for CVD risk assessment tools and the availability of generic statins. ...
